Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
James Weatherall, Nicola Barnes, Chloë Brown & Emmanuelle Préaud. (2011) Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective. Expert Review of Pharmacoeconomics & Outcomes Research 11:4, pages 411-414.
Read now
Read now
Joel W. Hay & Zheng-Yi Zhou. (2011) Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. Journal of Medical Economics 14:4, pages 516-525.
Read now
Read now
Rahul D. Ballal, Marc F. Botteman, Isaac Foley, Jennifer M. Stephens, Caitlyn T. Wilke & Ashish V. Joshi. (2008) Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Current Medical Research and Opinion 24:3, pages 753-768.
Read now
Read now
Jennifer M Stephens, Ashish V Joshi, Michael Sumner & Marc F Botteman. (2007) Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opinion on Pharmacotherapy 8:8, pages 1127-1136.
Read now
Read now
Articles from other publishers (23)
Maria del Carmen Rodríguez-Zepeda, Lourdes González, Amalia Bravo, Teresa Pompa, Salvador Silva, Rogelio Paredes, Jaime García, Mafalda Ramos, Lars Wilkinson & Mark Lamotte. (2018) Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico. Value in Health Regional Issues 17, pages 164-173.
Crossref
Crossref
Lucia S. D'Angiolella, Paolo A. Cortesi, Angiola Rocino, Antonio Coppola, Hamisa J. Hassan, Adele Giampaolo, Luigi P. Solimeno, Alessandra Lafranconi, Mariangela Micale, Sveva Mangano, Giacomo Crotti, Federica Pagliarin, Giancarlo Cesana & Lorenzo G. Mantovani. (2018) The socioeconomic burden of patients affected by hemophilia with inhibitors. European Journal of Haematology 101:4, pages 435-456.
Crossref
Crossref
Mina Golestani, Peyman Eshghi, Hamid Reza Rasekh, Abdol Majid Cheraghali, Jamshid Salamzadeh & Ali Imani. (2014) Bypassing Agents for Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors. Iranian Red Crescent Medical Journal 16:12.
Crossref
Crossref
Xunwei Duan, Mingqing Tang, Junping Zhang, Hao Yu & Ruian Xu. (2014) Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. Blood Coagulation & Fibrinolysis 25:6, pages 539-552.
Crossref
Crossref
Katarina Steen Carlsson & Erik E. Berntorp. 2014. Textbook of Hemophilia. Textbook of Hemophilia
489
494
.
V. Jimenez-Yuste, R. Núñez, J. A. Romero, B. Montoro & B. Espinós. (2013) Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain. Haemophilia 19:6, pages 841-846.
Crossref
Crossref
José Antonio Romero Garrido, José Félix Lucía Cuesta, Laia Febrer, Inma Trabal, Francisco J. Sabater, Leandro Lindner & Alicia Herrero. (2013) Estudio de los costes del desarrollo de inhibidores en pacientes con hemofilia A grave en España. PharmacoEconomics Spanish Research Articles 10:2, pages 69-78.
Crossref
Crossref
Roya Dolatkhah, Mohammad Reza Bazavar, Masoud Poureisa, Iraj Asvadi Kermani, Jalil Vaez Gharamaleki, Zohreh Sanaat, Jamal Eivazi Ziaei, Alireza Nikanfar, Ali Esfahani & Seyed Hadi Chavoshi. (2013) Successful Management of Total Knee Replacement in a High Responder Hemophilia Patient With a History of Inhibitor. Iranian Red Crescent Medical Journal 15:1, pages 18-20.
Crossref
Crossref
Matthew Gissel, Thomas Orfeo, Jonathan H. Foley & Saulius Butenas. (2012) Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia. Thrombosis Research 130:6, pages 948-955.
Crossref
Crossref
Peter Salaj, Miroslav Penka, Petr Smejkal, Vera Geierova, Petra Ovesná, Petr Brabec, Petr Cetkovsky, Radovan Kubes, Johan Mesterton & Peter Lindgren. (2012) Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: Haemophilia registry data from the Czech Republic. Thrombosis Research 129:5, pages e233-e237.
Crossref
Crossref
J. W. HAY & Z. Y. ZHOU. (2011) Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia, pages no-no.
Crossref
Crossref
Katarina Steen Carlsson & Erik Berntorp. 2010. Textbook of Hemophilia. Textbook of Hemophilia
409
414
.
M. A. ESCOBAR. (2010) Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia 16, pages 29-34.
Crossref
Crossref
C. KNIGHT, A. M. DANØ & T. KENNEDY‐MARTIN. (2010)
A Rebuttal to the Commentary of J. W. Hay and Z.‐Y. Zhou.
Haemophilia
2009; DOI:10.1111/j.1365‐2516.2009.02117.x: “Commentary on Knight
et al.
: A systematic review of the cost‐effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors”
. Haemophilia 16:2, pages 369-371.
Crossref
Crossref
M. N. D. DI MINNO, G. DI MINNO, M. DI CAPUA, A. M. CERBONE & A. COPPOLA. (2009) Cost of care of haemophilia with inhibitors. Haemophilia 16:1.
Crossref
Crossref
Lene Klixbüll Amby, Stephanie Seremetis, Achim Obergfell & Jens Bjerre. (2009) Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review. Blood Coagulation & Fibrinolysis 20:7, pages 488-493.
Crossref
Crossref
C. KNIGHT, A. M. DANØ & T. KENNEDY-MARTIN. (2009) A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia 15:2, pages 405-419.
Crossref
Crossref
C. W. YOU, S. Y. LEE & S. K. PARK. (2009) Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea. Haemophilia 15:1, pages 217-226.
Crossref
Crossref
Juan Luís Saucedo Figueredo, Susana Clemente Bautista, Luís Mendarte Barrenechea & José Bruno Montoro Ronsano. (2013) Eficiencia de los fármacos de origen biotecnológico en el marco terapéutico actual, según los estudios farmacoeconómicos disponibles. PharmacoEconomics Spanish Research Articles 5:4, pages 119-133.
Crossref
Crossref
WC LEE, A. V. JOSHI, S. WOOLFORD, M. SUMNER, M. BROWN, N. HADKER & C. L. PASHOS. (2008) Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment. Haemophilia 14:3, pages 454-465.
Crossref
Crossref
Bernadette Garvey. (2008) Rituximab in the treatment of autoimmune haematological disorders. British Journal of Haematology 141:2, pages 149-169.
Crossref
Crossref
Javier Batlle & María Fernanda López Fernández. (2007) Enseñanzas del factor VII activo recombinante. Diez años desde su autorización en la hemofilia complicada con inhibidor. Medicina Clínica 129:10, pages 382-386.
Crossref
Crossref
M. C OZELO, P. R VILLAÇA, J. O. S. C DE ALMEIDA, T. M. F BUENO, P. A. P DE MIRANDA, W. M HART & M KARAMALIS. (2007) A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 13:5, pages 462-469.
Crossref
Crossref